When you're adding visual effects to your footage, the best VFX software is essential. Whether you're a professional filmmaker or just making social media posts pop, these are my top picks for VFX ...

Less than two weeks after Zepbound-maker Eli Lilly reduced the price of the weight-loss drug, competitor Novo Nordisk said Wednesday it would cut the price of its popular weight-loss drug Wegovy ...

An icon in the shape of a lightning bolt. Impact Link Nvidia CEO Jensen Huang is unsure if export controls against China are effective national security measures for the US amid the artificial ...

Novo Nordisk shares rallied on Tuesday as a maker of a weight-loss drug alternative confirmed it won’t be selling it for much longer. Hims & Hers Health Inc.’s stock plunged last week when the ...

Investing.com -- Novo Nordisk shares climbed more than 3% premarket on Tuesday after Hims&Hers Health announced it may no longer sell compounded versions of semaglutide, the active ingredient in ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against the other oversold pharma stocks to buy according to analysts. On February 20, Emily Field ...

Novo can now meet the demand for Ozempic and Wegovy nationwide, the Food and Drug Administration said Friday. The ruling shows Novo’s confidence that the supply of Ozempic will be stable for now.

All semaglutide doses are now being “continuously shipped” to wholesalers and “meeting or exceeding expected U.S. demand,” Novo Nordisk said in a Friday press release. The company added ...

Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of Ozempic and Wegovy injections has been “resolved.” ...

However, in June 2024 Novo Nordisk said it was recognising a loss of around 5.7 billion Danish crowns (US$800 million) in relation to the drug after adverse clinical trial results.

Novo Nordisk is doing exceptionally well in the face of the challenges posed by Eli Lilly. So, sales of Ozempic and Wegovy amounted to DKK 53.7 billion in the fourth quarter of 2024, increasing by ...